Cerebrospinal Fluid Aβ and Tau Level Fluctuation in an Older Clinical Cohort
Authors:
- Joshua GohJGJoshua Goh
- Ming LiMLMing Li
- Marilyn AlbertMAMarilyn Albert
- Richard J. O’brienRORichard J. O’brien
Open Access
- 1 February 2012
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 69 (2) , 246-250
Abstract
Despite intensive research during the past 2 decades that has led to a better understanding of the pathogenesis of Alzheimer disease (AD), a therapy that alters its progression remains elusive. Several medications are available for symptomatic treatment of AD; however, none modifies the underlying evolution of the disease. Multiple trials1-3 of disease-modifying drugs in AD have failed thus far. One potential reason for this failure is the late stage in which these drugs are administered, a time at which neuronal injury may be irreversible. This has encouraged the identification of biomarkers for AD, which would facilitate early identification of the disease and in turn would enable trials of drug therapy when the course of the disease is still modifiable. Of all the biologically plausible biomarkers under study, only a few have been repeatedly identified by independent multicenter studies to be candidates that closely reflect the hallmark findings of the disease process. These include the serum apolipoprotein E allele status,4 positron emission tomographic imaging of brain amyloid,5,6 and the cerebrospinal fluid (CSF) levels of Aβ1-42, total tau, and phosphorylated tau on threonine 181 (p-tau181).7-9 The last 3 CSF biomarkers are particularly important, since they also have significant implications for disease-modifying therapy.10-12Keywords
This publication has 25 references indexed in Scilit:
- Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnestic Mild Cognitive ImpairmentArchives of Neurology, 2010
- Statins for the treatment of dementia2010
- Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly PeopleArchives of Neurology, 2010
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake CycleScience, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trialThe Lancet, 2008
- Biomarkers in the Diagnosis of Alzheimer’s Disease: Are We Ready?Journal of Geriatric Psychiatry and Neurology, 2006
- Effects of Processing and Storage Conditions on Amyloid β (1–42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical PracticeClinical Chemistry, 2005
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004